Cargando…
Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials
BACKGROUND: Ramosetron is a potent and selective serotonin type 3 receptor antagonist. This meta-analysis aimed to analyze the efficacy and safety of ramosetron for irritable bowel syndrome with diarrhea (IBS-D). METHODS: Pubmed, MEDLINE, EMBASE and the Cochrane Library were searched for randomized...
Autores principales: | Qi, Qingqing, Zhang, Yan, Chen, Feixue, Zuo, Xiuli, Li, Yanqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759234/ https://www.ncbi.nlm.nih.gov/pubmed/29310568 http://dx.doi.org/10.1186/s12876-017-0734-2 |
Ejemplares similares
-
Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome
por: Chiba, Toshimi, et al.
Publicado: (2013) -
Are Solifenacin and Ramosetron Really Ideal to Treat Irritable Bowel Syndrome?
por: Chang, Full-Young
Publicado: (2012) -
Efficacy of Ramosetron in Male Patients With Irritable Bowel Syndrome With Diarrhea (Neurogastroenterol Motil 2011;23:1098-1104)
por: Cha, Bong Ki, et al.
Publicado: (2012) -
Are Solifenacin and Ramosetron Really Ideal to Treat Irritable Bowel Syndrome?: Author's Reply
por: Suzuki, Hidekazu, et al.
Publicado: (2012) -
Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea
por: Ida, Motoko, et al.
Publicado: (2017)